Literature DB >> 24729070

Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.

Orin Bloch1, Andrew T Parsa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24729070      PMCID： PMC3984567          DOI： 10.1093/neuonc/nou054

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

1.  Surgery, a prognostic marker for progression-free survival?

Authors:  Marc C Chamberlain; Daniel L Silbergeld
Journal:  Neuro Oncol       Date:  2012-04       Impact factor: 12.300

2.  Is there a role for whole brain radiotherapy in the treatment of leptomeningeal metastases?

Authors:  Marc C Chamberlain; Keith Eaton
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

3.  Is graded prognostic assessment an improvement compared with radiation therapy oncology group's recursive partitioning analysis classification for brain metastases?

Authors:  Marc C Chamberlain; Daniel L Silbergeld
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

4.  Are prognostic factors for leptomeningeal metastases defined sufficiently to permit tailored treatment?

Authors:  Marc C Chamberlain; Bernardo H L Goulart
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

5.  Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).

Authors:  Marc C Chamberlain
Journal:  Neuro Oncol       Date:  2011-05       Impact factor: 12.300

6.  Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?

Authors:  Marc C Chamberlain
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

7.  Does RTOG 9802 change practice with respect to newly diagnosed low-grade glioma?

Authors:  Marc C Chamberlain
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

8.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

9.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

10.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115
View more
  11 in total

Review 1.  Optimizing glioblastoma resection: intraoperative mapping and beyond.

Authors:  Joseph A Osorio; Manish K Aghi
Journal:  CNS Oncol       Date:  2014

Review 2.  Immunotherapy for Brain Tumors.

Authors:  Lan B Hoang-Minh; Duane A Mitchell
Journal:  Curr Treat Options Oncol       Date:  2018-10-11

3.  Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.

Authors:  Paula Alcaide-Leon; Tracy L Luks; Marisa Lafontaine; Janine M Lupo; Hideho Okada; Jennifer L Clarke; Javier E Villanueva-Meyer
Journal:  J Neurooncol       Date:  2019-11-14       Impact factor: 4.130

Review 4.  Heat shock protein vaccines against glioblastoma: from bench to bedside.

Authors:  Leonel Ampie; Winward Choy; Jonathan B Lamano; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2015-06-21       Impact factor: 4.130

5.  Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.

Authors:  Evan Winograd; Isabelle Germano; Patrick Wen; Jeffrey J Olson; D Ryan Ormond
Journal:  J Neurooncol       Date:  2021-10-25       Impact factor: 4.130

Review 6.  Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.

Authors:  Alicia Tosoni; Enrico Franceschi; Rosalba Poggi; Alba A Brandes
Journal:  Curr Treat Options Oncol       Date:  2016-09

Review 7.  Neuro-oncology biotech industry progress report.

Authors:  Shamik Chakraborty; Imithri Bodhinayake; Amrit Chiluwal; David J Langer; Rosamaria Ruggieri; Marc Symons; John A Boockvar
Journal:  J Neurooncol       Date:  2016-02-20       Impact factor: 4.506

8.  The future of high-grade glioma: Where we are and where are we going.

Authors:  Emilie Le Rhun; Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2015-02-13

9.  Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.

Authors:  Xiudong Guan; Md Nabiul Hasan; Gulnaz Begum; Gary Kohanbash; Karen E Carney; Victoria M Pigott; Anders I Persson; Maria G Castro; Wang Jia; Dandan Sun
Journal:  Cell Death Dis       Date:  2018-09-27       Impact factor: 8.469

10.  Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials.

Authors:  Wenlin Chen; Delin Liu; Penghao Liu; Ziren Kong; Yaning Wang; Yu Wang; Wenbin Ma
Journal:  Chin J Cancer Res       Date:  2021-06-30       Impact factor: 4.026
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.